S1PR1 and myeloid sarcoma: Structurally, siponimod is an alkoxyimino derivative of fingolimod, developed by optimizing the initial structure to increase its potency for S1PR1 and selectivity against S1PR3, thus increasing the therapeutic potential for MS and decreasing the risks of side effects [21].